Type III Prostatitis
Conditions
Interventions
Control group:Tamsulosin Hydrochloride Sustained Release Capsule, 0.2mg, qn
Experimental group:Xialiqi capsule, 3 capsules, tid+Tamsulosin Hydrochloride Sustained Release Capsule, 0.2mg, qn
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) It conforms to the diagnostic criteria of Type III Prostatitis. (2) It conforms to the standard of Syndrome of Spleen-Kidney Qi Deficiency and Damp-Heat Stasis. (3) Aged between 18 and 50. (4) NIH-CPSI=10. (5) Voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with type I, II and IV prostatitis. (2) Those who have used drugs or other related treatments for chronic prostatitis in the past 2 weeks. (3) Patients with benign prostatic hyperplasia, prostate tumor, epididymitis, seminal vesiculitis, urinary tract disease, severe neurosis diabetes, pelvic surgery history, etc. (4) Patients with coronary heart disease, serious primary cardiovascular disease, liver disease, kidney disease, hematologic disease, pulmonary disease, or serious disease affecting their survival, such as tumor or AIDS, should not be selected. (5) ALT, AST or BUN exceeding 2 times the upper limit of normal value, or eGFR<45ml/min/1.73m2. (6) Postural hypotension. (7) Non-prostatitis caused by the lower abdomen, perineum, lumbosacral and other painful diseases. (8) Patients with allergic constitution or allergy to test drug composition, and patients with a history of sulfonamide drug allergy. (9) Suspected or had a history of alcohol or drug abuse, or had other diseases that, according to the judgment of the investigator, reduced the possibility of enrollment or complicated enrollment, such as frequent changes in the work environment, which could easily lead to loss of follow-up. (10) Patients receiving CYP3A4 or CYP2D6 potent inhibitors (such as Ketoconazole and paroxetine), other adrenergic blockers and cimetidine. (11) Patients who are participating in clinical trials of other drugs, or have participated in a drug clinical trial within the past one month. (12) Other patients deemed unsuitable for the clinical study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIH-CPSI score; | — |
Secondary
| Measure | Time frame |
|---|---|
| urinalysis;Blood routine;Urinary ultrasound;liver function;Routine prostatic fluid;Routine stool + occult blood;renal function;Prostatic fluid culture;Uroflowmetry;ECG; | — |
Countries
China
Contacts
Public ContactGAO ZHAN
Outcome results
None listed